333 related articles for article (PubMed ID: 25060555)
1. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
2. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.
Triulzi T; Casalini P; Sandri M; Ratti M; Carcangiu ML; Colombo MP; Balsari A; Ménard S; Orlandi R; Tagliabue E
PLoS One; 2013; 8(2):e56761. PubMed ID: 23441215
[TBL] [Abstract][Full Text] [Related]
3. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
4. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
5. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
[TBL] [Abstract][Full Text] [Related]
6. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.
Fredlund E; Staaf J; Rantala JK; Kallioniemi O; Borg A; Ringnér M
Breast Cancer Res; 2012 Jul; 14(4):R113. PubMed ID: 22839103
[TBL] [Abstract][Full Text] [Related]
7. Prognostic stromal gene signatures in breast cancer.
Winslow S; Leandersson K; Edsjö A; Larsson C
Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
[TBL] [Abstract][Full Text] [Related]
8. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.
Yao M; Yu E; Staggs V; Fan F; Cheng N
Mod Pathol; 2016 Aug; 29(8):810-23. PubMed ID: 27125354
[TBL] [Abstract][Full Text] [Related]
10. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
[TBL] [Abstract][Full Text] [Related]
11. Stromal responses among common carcinomas correlated with clinicopathologic features.
Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
[TBL] [Abstract][Full Text] [Related]
12. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
13. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Magbanua MJ; Wolf DM; Yau C; Davis SE; Crothers J; Au A; Haqq CM; Livasy C; Rugo HS; ; Esserman L; Park JW; van 't Veer LJ
Breast Cancer Res; 2015 May; 17(1):73. PubMed ID: 26021444
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of the tumor microenvironment during breast cancer progression.
Ma XJ; Dahiya S; Richardson E; Erlander M; Sgroi DC
Breast Cancer Res; 2009; 11(1):R7. PubMed ID: 19187537
[TBL] [Abstract][Full Text] [Related]
15. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
16. A genomic ruler to assess oncogenic transition between breast tumor and stroma.
Dhage S; Ernlund A; Ruggles K; Axelrod D; Berman R; Roses D; Schneider RJ
PLoS One; 2018; 13(10):e0205602. PubMed ID: 30325954
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
18. A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer.
Block CJ; Dyson G; Campeanu IJ; Watza D; Ratnam M; Wu G
Sci Rep; 2019 Nov; 9(1):17807. PubMed ID: 31780722
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
[TBL] [Abstract][Full Text] [Related]
20. A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.
Speers C; Chang SL; Pesch A; Ritter C; Olsen E; Chandler B; Moubadder L; Liu M; Cameron M; Michmerhuizen A; Wilder-Romans K; Zhao SG; Nyati S; Bartelink H; Feng FY; Pierce LJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):686-696. PubMed ID: 32434041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
